The effect of jaundice on the generation of anti-gastrin antibodies in G17DT immunized patients with advanced pancreatic cancer

Takhar, Arjun; Gilliam, A. D.; Watson, Sue‐Ann; Henwood, Mark; Broome, P.; Beckingham, I. J.

doi:10.1016/j.ejso.2005.08.008

Cited by 5 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thirty five of 41 patients produced a gastrin-17 antibody response. There was no correlation between maximum antibody response and bilirubin level at week 0 or 12 [26]. The median survival for the antibody responders was 204 days which was comparable to the previous study [25].…”

Section: Gastrinsupporting

confidence: 87%

Monoclonal Antibody Therapies Targeting Pancreatic Ductal Adenocarcinoma

Engelhardt¹,

Riley²,

Cooke³

et al. 2006

CDDT

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDA) is a lethal disease with a poor prognosis where incidence mirrors mortality. Gemcitabine and gemcitabine plus erlotinib (epidermal growth factor receptor tyrosine kinase inhibitor) are the only FDA approved therapies for unresectable or metastatic PDA and are at best palliative. Hence, considerable efforts have been initiated to identify novel targets for monoclonal antibody (Mab) therapies that may safely and effectively be combined with gemcitabine. Mabs to cell surface receptors and/or their ligands have shown efficacy in pre-clinical and clinical studies in both solid and hematological malignancies and can safely be given with chemotherapy. A number of clinical trials have evaluated the safety and efficacy of Mabs targeting the tumor and/or tumor micro-environment and in combination with chemotherapy for PDA with very little success. Here we review the rationale for Mab therapies, targeted clinical trials, rational basis for target selection, pre-clinical models and promising novel cell surface targets and/or growth factor ligands that are amenable to ongoing and future Mab therapies that hold promise and hope for patients and their families with this devastating disease.

show abstract

Section: Gastrinsupporting

confidence: 87%

Monoclonal Antibody Therapies Targeting Pancreatic Ductal Adenocarcinoma

Engelhardt¹,

Riley²,

Cooke³

et al. 2006

CDDT

View full text Add to dashboard Cite

show abstract

Novel therapeutic approaches in the treatment of advanced pancreatic carcinoma

Zalatnai

2007

Cancer Treatment Reviews

View full text Add to dashboard Cite

An International Multicenter Randomized Controlled Trial of G17DT in Patients With Pancreatic Cancer

Gilliam¹,

Broome²,

Topuzov³

et al. 2012

Pancreas

View full text Add to dashboard Cite

A total of 154 patients were recruited: 79 G17DT and 75 placebo. A final analysis of the intention-to-treat population, using a proportional hazards model, stratifying by disease stage and adjusting for interim analysis, gave a hazard ratio for mortality of 0.75 (95% confidence interval, 0.51-1.10, P = 0.138; G17DT/placebo). A conventional analysis without adjustment for disease stage or interim analysis, censoring for chemotherapy and excluding protocol violators, gave median survival periods of 151 (G17DT) and 82 days (placebo) (log-rank test, P = 0.03).Patients developing anti-G17DT responses (73.8%) survived longer than nonresponders or those on placebo (median survival, 176 vs 63 vs 83; log-rank test, P = 0.003). G17DT was well tolerated.

show abstract

The effect of jaundice on the generation of anti-gastrin antibodies in G17DT immunized patients with advanced pancreatic cancer

Cited by 5 publications

References 12 publications

Monoclonal Antibody Therapies Targeting Pancreatic Ductal Adenocarcinoma

Monoclonal Antibody Therapies Targeting Pancreatic Ductal Adenocarcinoma

Novel therapeutic approaches in the treatment of advanced pancreatic carcinoma

An International Multicenter Randomized Controlled Trial of G17DT in Patients With Pancreatic Cancer

Contact Info

Product

Resources

About